Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Sarcoma

July 21, 2016

Join Suzanne George, MD and Chandrajit P. Raut, MD, MSc from Dana-Farber Cancer Institute as they present their expertise on a range of cases pertaining to sarcoma.

Sarcomas constitute a heterogeneous group of rare solid tumors of mesenchymal cell origin with distinct clinical and pathologic features. They can develop in soft tissue (including fat, muscle, nerve and nerve sheath, blood vessels, and other connective tissues) or in bone. Soft-tissue sarcoma most commonly metastasizes to the lungs; tumors arising in the abdominal cavity more commonly metastasize to the liver and peritoneum.

Treatment approach for soft-tissue sarcoma is determined by tumor type and extent of disease. Clinicians should have knowledge of combination and single-agent systemic therapy regimens with demonstrated efficacy against specific histologic subtypes of soft-tissue sarcoma. Additionally, clinicians should be aware of developing clinical trial data and recent FDA drug approvals for treating soft-tissue sarcoma.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Select an optimal treatment approach and sequence when reviewing potential medical, radiologic, and/or surgical options for treatment of soft-tissue sarcoma.
  • Evaluate the clinical evidence base for current and emerging systemic therapies for treating soft-tissue sarcoma.
  • Review the data from developing clinical trials in soft-tissue sarcoma.
Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
07/20/2016
Course expires: 
09/16/2016
Event starts: 
07/21/2016 - 12:00pm
Event ends: 
07/21/2016 - 1:00pm
Cost:
$0.00

Suzanne George, MD
Dana-Farber Cancer Institute

Chandrajit P. Raut, MD, MSc
Brigham and Women’s Hospital

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code and Approval Number will be posted prior to activity date.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-077-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
07/20/2016
Course expires: 
09/16/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing